Abbisko Cayman (HKSE:02256) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Debt-to-Equity?

Abbisko Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$11.61 Mil. Abbisko Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$27.47 Mil. Abbisko Cayman's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$2,166.89 Mil. Abbisko Cayman's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Abbisko Cayman's Debt-to-Equity or its related term are showing as below:

HKSE:02256' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.02 Max: 0.02
Current: 0.02

During the past 5 years, the highest Debt-to-Equity Ratio of Abbisko Cayman was 0.02. The lowest was -0.02. And the median was 0.02.

HKSE:02256's Debt-to-Equity is ranked better than
87.83% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:02256: 0.02

Abbisko Cayman Debt-to-Equity Historical Data

The historical data trend for Abbisko Cayman's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Debt-to-Equity Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.02

0.02

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.02	0.02	0.02	0.02	0.02

Competitive Comparison of Abbisko Cayman's Debt-to-Equity

For the Biotechnology subindustry, Abbisko Cayman's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Debt-to-Equity falls into.

Abbisko Cayman Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Abbisko Cayman's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.605	+	27.469)	/	2166.888
	=	0.02

Abbisko Cayman's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.605	+	27.469)	/	2166.888
	=	0.02

Abbisko Cayman (HKSE:02256) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Abbisko Cayman Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (HKSE:02256) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

8ZD:Germany

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Executives

Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you
Xu Yao-chang	2101 Beneficial owner
Yu Hongping	2501 Other
Chen Zhui	2501 Other
Futu Trustee Limited	2301 Trustee
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Yu Hongping	2501 Other
Morgan Stanley	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited	2301 Trustee
Computershare Hong Kong Trustees Limited	2301 Trustee
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you

Abbisko Cayman (HKSE:02256) Headlines

No Headlines